Long-term survival after photodynamic therapy for esophageal cancer

Sibille, Alain; Lambert, René; Souquet, Jean-Christophe; Sabben, G.; Descos, F.

doi:10.1016/0016-5085(95)90058-6

Cited by 217 publications

(116 citation statements)

References 28 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…[22][23][24][25][26][27][28] The response and safety need to be established for each tumor type and location. 28,41 This prospective, single-arm phase II trial rested on 3 assumptions: (1) PDT could achieve a high rate of local tumor response in the biliary tree; (2) progressive tumor occlusion of the liver hilus is the underlying cause of early death 1,[19][20][21] ; (3) less than 50% of historic controls with biliary endoprostheses survived for 6 months after diagnosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival

et al. 2000

View full text Add to dashboard Cite

Median survival time of nonresectable hilar bile duct cancer is only 4 to 6 months owing to tumor spread in the biliary tree, refractory cholestasis, and sepsis or liver failure. We explored whether local photodynamic therapy of nonresectable bile duct cancer could improve survival. A sample size of 23 patients is required to detect an increase in 6-month survival rate from less than 50% to greater than 70% in a single-arm phase-II trial with a statistical power of 80% (Fleming's single step procedure; ␣ ‫؍‬ 0.05). Twentythree consecutive patients (8 women, 15 men; 67 ؎ 14 years) with nonresectable bile duct cancer (Bismuth type III n ‫؍‬ 2, type IV n ‫؍‬ 21) were treated with photodynamic therapy and biliary endoprosthesis. Photofrin (QLT Pharmaceuticals, Vancouver, Canada) (2 mg/kg body weight intravenously) was photoactivated after 1 to 4 days with laser light (630 nm; 242 J/cm 2 ) via endoscopic retrograde access. The 6-month survival rate was 91% after diagnosis and 74% after start of photodynamic therapy (30-day mortality rate was 4%) at a median follow-up time of 10.3 months after diagnosis. Causes of death were tumor progression (n ‫؍‬ 9) and bacterial infections (n ‫؍‬ 4). The median rate of local tumor response was 74%, 54%, 29%, and 67% after the first, second, third, fourth, and fifth photodynamic therapy. Time to progression ranged from 3 to 8 months. All patients, except 1 with diffuse liver metastases, improved in cholestasis, performance, and quality of life. Photodynamic therapy can prevent tumor occlusion of hilar bile ducts. The apparent benefit in survival time should be confirmed in a controlled trial versus palliation by endoprosthesis only. (HEPATOLOGY 2000;31:291-298.)Hilar bile duct cancer is fraught with a very poor prognosis. 1,2 Tumors limited to the common bile duct, the bifurcation, or the bifurcation and the intrahepatic ducts of either the right or left lobe, types I, II, IIIa, and IIIb according to Bismuth, 3 may be curatively resectable with a 5-year survival rate of 9% to 21%, 4-8 and 26% to 30% in selected series. 9,10

show abstract

Section: Discussionmentioning

confidence: 99%

“…1,20,21 Photodynamic therapy (PDT) has achieved remarkable local regression of malignant tumors. [22][23][24][25] PDT is a 2-step procedure. A photosensitizing drug known to accumulate in tumor cells is administered and then the tumor is exposed to laser light of appropriate wave length.…”

mentioning

confidence: 99%

Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival

et al. 2000

View full text Add to dashboard Cite

show abstract

“…1995). oesophageal cancer (Sibille et al 1995). a vaniety of skin cancers (Dougherty et al, 1978) and gastric cancer (Hayata et al 1985).…”

mentioning

confidence: 99%

Cell cycle phase influences tumour cell sensitivity to aminolaevulinic acid-induced photodynamic therapy in vitro

Wyld

Smith²,

Lawry³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

“…PDT is also effective as a curative treatment for small superficial tumors in the esophagus [80]. A CR rate of 87% at 6 months and a 5-year overall survival rate of 25% were achieved in a group of 123 patients treated with porfimer sodium-mediated PDT [81]. Comparable results were also obtained using mTHPC as the photosensitizer [82].…”

Section: Esophageal Cancermentioning

confidence: 97%

Photodynamic Therapy in Oncology

Triesscheijn¹,

et al. 2006

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is increasingly being recognized as an attractive, alternative treatment modality for superficial cancer. Treatment consists of two relatively simple procedures: the administration of a photosensitive drug and illumination of the tumor to activate the drug. Efficacy is high for small superficial tumors and, except for temporary skin photosensitization, there are no long-term side effects if appropriate protocols are followed. Healing occurs with little or no scarring and the procedure can be repeated without cumulative toxicity. Considering the efficacy and lack of long-term toxicity of PDT, and the fact that the first treatment of cancer with PDT was done more than 100 years ago, one might expect that this treatment had already become an established therapy. However, PDT is currently offered in only a few selected centers, although it is slowly gaining acceptance as an alternative to conventional cancer therapies. Here, we show the developmental steps PDT underwent and summarize the current clinical applications. The data show that, when properly used, PDT is an effective alternative treatment option in oncology. The

show abstract

Long-term survival after photodynamic therapy for esophageal cancer

Cited by 217 publications

References 28 publications

Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival

Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival

Cell cycle phase influences tumour cell sensitivity to aminolaevulinic acid-induced photodynamic therapy in vitro

Photodynamic Therapy in Oncology

Contact Info

Product

Resources

About